HJ SCIENCE-B(06132.HK) closed 56.89% lower, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends

NewTimeSpace News: HJ Science Co., Ltd. (06132.HK) was officially listed on the Main Board of the Hong Kong Stock Exchange on 23 June 2026. The stock posted a weak debut performance, closing at HK$35.26, down HK$46.54 or 56.89% versus the offer price of HK$81.8. Its intraday high touched HK$82, with full-day turnover hitting HK$602 million and the latest market capitalisation at HK$2.595 billion.

Founded in 2017, HJ Science is a clinical-stage biotech company established by a team of industry experts dedicated to developing therapies for autoimmune, metabolic and oncological diseases. It owns three core products namely HJ787, HJ178 and HJ891, all self-developed small-molecule Class 1 innovative drugs approved by the NMPA. In terms of financial performance, the Company generated revenue of RMB1.8 million and RMB12.982 million in 2024 and 2025 respectively, while total loss and comprehensive expenses for the year amounted to RMB220 million and RMB135 million correspondingly.